CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 516 enrolled
Drug / intervention
Desirudindrug
Likely dose
Desirudin 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00913133
NCT00913133Phase 4Completed
CompareCT.gov

Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)

Canyon Pharmaceuticals, Inc.·interventional·Posted Jun 4, 2009·Updated Jan 10, 2013

In Brief

A Phase 4 clinical trial evaluating Desirudin for Thrombosis. Completed, enrolled 516 participants across 16 sites.

Detailed Summary

The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 4, 2009
Enrollment StartMar 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.1 years ago

Interventions

Desirudindrug

Desirudin SC 15mg q12h